Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration.
Finger RP, Schmitz-Valckenberg S, Schmid M, Rubin GS, Dunbar H, Tufail A, Crabb DP, Binns A, Sánchez CI, Margaron P, Normand G, Durbin MK, Luhmann UFO, Zamiri P, Cunha-Vaz J, Asmus F, Holz FG; on behalf of the MACUSTAR consortium. Finger RP, et al. Among authors: dunbar h. Ophthalmologica. 2019;241(2):61-72. doi: 10.1159/000491402. Epub 2018 Aug 28. Ophthalmologica. 2019. PMID: 30153664 Free PMC article. Review.
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
Strauss RW, Ho A, Muñoz B, Cideciyan AV, Sahel JA, Sunness JS, Birch DG, Bernstein PS, Michaelides M, Traboulsi EI, Zrenner E, Sadda S, Ervin AM, West S, Scholl HP; Progression of Stargardt Disease Study Group. Strauss RW, et al. Ophthalmology. 2016 Apr;123(4):817-28. doi: 10.1016/j.ophtha.2015.12.009. Epub 2016 Jan 16. Ophthalmology. 2016. PMID: 26786511
Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention-MACUSTAR.
Terheyden JH, Holz FG, Schmitz-Valckenberg S, Lüning A, Schmid M, Rubin GS, Dunbar H, Tufail A, Crabb DP, Binns A, Sánchez CI, Hoyng C, Margaron P, Zakaria N, Durbin M, Luhmann U, Zamiri P, Cunha-Vaz J, Martinho C, Leal S, Finger RP; MACUSTAR consortium. Terheyden JH, et al. Among authors: dunbar h. Trials. 2020 Jul 18;21(1):659. doi: 10.1186/s13063-020-04595-6. Trials. 2020. PMID: 32682441 Free PMC article.
Use of Composite End Points in Early and Intermediate Age-Related Macular Degeneration Clinical Trials: State-of-the-Art and Future Directions.
Terheyden JH, Schmitz-Valckenberg S, Crabb DP, Dunbar H, Luhmann UFO, Behning C, Schmid M, Silva R, Cunha-Vaz J, Tufail A, Weissgerber G, Leal S, Holz FG, Finger RP; on behalf of the MACUSTAR Consortium. Terheyden JH, et al. Among authors: dunbar h. Ophthalmologica. 2021;244(5):387-395. doi: 10.1159/000513591. Epub 2020 Dec 7. Ophthalmologica. 2021. PMID: 33285549 Free article. Review.
90 results